Livzon Pharmaceutical Group (HK:1513) has released an update.
Livzon Pharmaceutical Group’s financial report for the third quarter of 2024 reveals a slight decline in operating income by 5.59% year-on-year, while net profit attributable to shareholders increased by 7.45%. The company’s basic earnings per share rose by 8%, indicating a steady performance amidst the challenging market conditions.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.
